{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:43:06Z","timestamp":1780454586803,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11060-025-05149-z","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:12:35Z","timestamp":1758039155000},"page":"1331-1341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of EGFR mutation subtypes and TKI generations on clinical outcomes in lung adenocarcinoma patients with brain metastases treated with gamma knife radiosurgery"],"prefix":"10.1007","volume":"175","author":[{"given":"Haewon","family":"Roh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juwhan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"5149_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12032-014-0228-9","volume":"31","author":"A Sekine","year":"2014","unstructured":"Sekine A, Satoh H, Iwasawa T, Tamura K, Hayashihara K, Saito T, Kato T, Arai M, Okudela K, Ohashi K, Ogura T (2014) Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy. Med Oncol 31:228. https:\/\/doi.org\/10.1007\/s12032-014-0228-9","journal-title":"Med Oncol"},{"key":"5149_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2007.02.006","volume":"57","author":"F Ampil","year":"2007","unstructured":"Ampil F, Caldito G, Milligan S, Mills G, Nanda A (2007) The elderly with synchronous non-small cell lung cancer and solitary brain metastasis: does palliative thoracic radiotherapy have a useful role? Lung Cancer 57:60\u201365. https:\/\/doi.org\/10.1016\/j.lungcan.2007.02.006","journal-title":"Lung Cancer"},{"key":"5149_CR3","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","volume":"19","author":"SN Waqar","year":"2018","unstructured":"Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L, Govindan R, Gao F, Puri V, Morgensztern D (2018) Non-small-cell lung Cancer with brain metastasis at presentation. Clin Lung Cancer 19:e373\u2013e379. https:\/\/doi.org\/10.1016\/j.cllc.2018.01.007","journal-title":"Clin Lung Cancer"},{"key":"5149_CR4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijrobp.2014.02.025","volume":"89","author":"Z Ji","year":"2014","unstructured":"Ji Z, Bi N, Wang J, Hui Z, Xiao Z, Feng Q, Zhou Z, Chen D, Lv J, Liang J, Fan C, Liu L, Wang L (2014) Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. Int J Radiat Oncol Biol Phys 89:330\u2013337. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.02.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5149_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1200\/JCO.2004.05.128","volume":"22","author":"CA Meyers","year":"2004","unstructured":"Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22:157\u2013165. https:\/\/doi.org\/10.1200\/JCO.2004.05.128","journal-title":"J Clin Oncol"},{"key":"5149_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/OTT.S23165","volume":"6","author":"V Nelson","year":"2013","unstructured":"Nelson V, Ziehr J, Agulnik M, Johnson M (2013) Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 6:135\u2013143. https:\/\/doi.org\/10.2147\/OTT.S23165","journal-title":"Onco Targets Ther"},{"key":"5149_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1165\/rcmb.2009-0206TR","volume":"42","author":"NH Heintz","year":"2010","unstructured":"Heintz NH, Janssen-Heininger YM, Mossman BT (2010) Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 42:133\u2013139. https:\/\/doi.org\/10.1165\/rcmb.2009-0206TR","journal-title":"Am J Respir Cell Mol Biol"},{"key":"5149_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJM199009063231003","volume":"323","author":"DT Janerich","year":"1990","unstructured":"Janerich DT, Thompson WD, Varela LR, Greenwald P, Chorost S, Tucci C, Zaman MB, Melamed MR, Kiely M, McKneally MF (1990) Lung cancer and exposure to tobacco smoke in the household. N Engl J Med 323:632\u2013636. https:\/\/doi.org\/10.1056\/NEJM199009063231003","journal-title":"N Engl J Med"},{"key":"5149_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.6004\/jnccn.2017.0050","volume":"15","author":"DS Ettinger","year":"2017","unstructured":"Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D\u2019Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr., Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2017) Non-Small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:504\u2013535. https:\/\/doi.org\/10.6004\/jnccn.2017.0050","journal-title":"J Natl Compr Canc Netw"},{"key":"5149_CR10","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1097\/JTO.0b013e31829f684a","volume":"8","author":"VH Lee","year":"2013","unstructured":"Lee VH, Tin VP, Choy TS, Lam KO, Choi CW, Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, Liu J, Shek TW, Kwong DL, Leung TW, Wong MP (2013) Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. J Thorac Oncol 8:1148\u20131155. https:\/\/doi.org\/10.1097\/JTO.0b013e31829f684a","journal-title":"J Thorac Oncol"},{"key":"5149_CR11","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11060-019-03282-0","volume":"145","author":"S Yomo","year":"2019","unstructured":"Yomo S, Serizawa T, Yamamoto M, Higuchi Y, Sato Y, Shuto T, Akabane A, Jokura H, Kawagishi J, Aoyama H (2019) The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after gamma knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI). J Neurooncol 145:151\u2013157. https:\/\/doi.org\/10.1007\/s11060-019-03282-0","journal-title":"J Neurooncol"},{"key":"5149_CR12","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947\u2013957. https:\/\/doi.org\/10.1056\/NEJMoa0810699","journal-title":"N Engl J Med"},{"key":"5149_CR13","doi-asserted-by":"publisher","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) North-East Japan Study G Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380\u20132388 https:\/\/doi.org\/10.1056\/NEJMoa0909530","DOI":"10.1056\/NEJMoa0909530"},{"key":"5149_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s11523-021-00839-w","volume":"16","author":"YN Lamb","year":"2021","unstructured":"Lamb YN (2021) Osimertinib: A review in previously untreated, EGFR Mutation-Positive, advanced NSCLC. Target Oncol 16:687\u2013695. https:\/\/doi.org\/10.1007\/s11523-021-00839-w","journal-title":"Target Oncol"},{"key":"5149_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/1078-0432.CCR-19-1871","volume":"27","author":"N Colclough","year":"2021","unstructured":"Colclough N, Chen K, Johnstrom P, Strittmatter N, Yan Y, Wrigley GL, Schou M, Goodwin R, Varnas K, Adua SJ, Zhao M, Nguyen DX, Maglennon G, Barton P, Atkinson J, Zhang L, Janefeldt A, Wilson J, Smith A, Takano A, Arakawa R, Kondrashov M, Malmquist J, Revunov E, Vazquez-Romero A, Moein MM, Windhorst AD, Karp NA, Finlay MRV, Ward RA, Yates JWT, Smith PD, Farde L, Cheng Z, Cross DAE (2021) Preclinical comparison of the Blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res 27:189\u2013201. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1871","journal-title":"Clin Cancer Res"},{"key":"5149_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s11523-018-0566-1","volume":"13","author":"M Hochmair","year":"2018","unstructured":"Hochmair M (2018) Medical treatment options for patients with epidermal growth factor receptor Mutation-Positive Non-Small cell lung Cancer suffering from brain metastases and\/or leptomeningeal disease. Target Oncol 13:269\u2013285. https:\/\/doi.org\/10.1007\/s11523-018-0566-1","journal-title":"Target Oncol"},{"key":"5149_CR17","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","volume":"22","author":"P Ballard","year":"2016","unstructured":"Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnstrom P, Varnas K, Malmquist J, Thress KS, Janne PA, Cross D (2016) Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-Mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 22:5130\u20135140. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0399","journal-title":"Clin Cancer Res"},{"key":"5149_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1056\/NEJMoa040938","volume":"350","author":"TJ Lynch","year":"2004","unstructured":"Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129\u20132139. https:\/\/doi.org\/10.1056\/NEJMoa040938","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"5149_CR19","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/onc.2009.198","volume":"28","author":"AF Gazdar","year":"2009","unstructured":"Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28(Suppl 1):S24\u201331. https:\/\/doi.org\/10.1038\/onc.2009.198","journal-title":"Oncogene"},{"key":"5149_CR20","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1158\/1078-0432.CCR-04-1245","volume":"10","author":"SF Huang","year":"2004","unstructured":"Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF (2004) High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195\u20138203. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1245","journal-title":"Clin Cancer Res"},{"key":"5149_CR21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/1759-7714.12085","volume":"5","author":"N Qin","year":"2014","unstructured":"Qin N, Yang X, Zhang Q, Li X, Zhang H, Lv J, Wu Y, Wang J, Zhang S (2014) Efficacy of Icotinib treatment in patients with stage iiib\/iv non-small cell lung cancer. Thorac Cancer 5:243\u2013249. https:\/\/doi.org\/10.1111\/1759-7714.12085","journal-title":"Thorac Cancer"},{"key":"5149_CR22","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1158\/1078-0432.CCR-11-2353","volume":"18","author":"KP Chung","year":"2012","unstructured":"Chung KP, Wu SG, Wu JY, Yang JC, Yu CJ, Wei PF, Shih JY, Yang PC (2012) Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Clin Cancer Res 18:3470\u20133477. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2353","journal-title":"Clin Cancer Res"},{"key":"5149_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3171\/2021.9.JNS211373","volume":"137","author":"GY Chiou","year":"2022","unstructured":"Chiou GY, Chiang CL, Yang HC, Shen CI, Wu HM, Chen YW, Chen CJ, Luo YH, Hu YS, Lin CJ, Chung WY, Shiau CY, Guo WY, Pan DH, Lee CC (2022) Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases. J Neurosurg 137:563\u2013570. https:\/\/doi.org\/10.3171\/2021.9.JNS211373","journal-title":"J Neurosurg"},{"key":"5149_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.lungcan.2018.03.013","volume":"119","author":"S Yomo","year":"2018","unstructured":"Yomo S, Oda K (2018) Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients. Lung Cancer 119:120\u2013126. https:\/\/doi.org\/10.1016\/j.lungcan.2018.03.013","journal-title":"Lung Cancer"},{"key":"5149_CR25","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3171\/2024.7.JNS24310","volume":"142","author":"SA Liu","year":"2025","unstructured":"Liu SA, Lee CC, Yang HC, Huang WL, Huang YH, Chung WY, Shi HY (2025) Clinical outcomes and cost-utility analysis of GKRS plus TKIs versus TKIs in patients with EGFR-mutant lung adenocarcinoma and brain metastases: a Markov decision model. J Neurosurg 142:1710\u20131719. https:\/\/doi.org\/10.3171\/2024.7.JNS24310","journal-title":"J Neurosurg"},{"key":"5149_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J (2018) CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-Mutated advanced Non-Small-Cell lung Cancer. J Clin Oncol: JCO2018783118. https:\/\/doi.org\/10.1200\/JCO.2018.78.3118","journal-title":"J Clin Oncol: JCO2018783118"},{"key":"5149_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10585-020-10022-6","volume":"37","author":"SW Lee","year":"2020","unstructured":"Lee SW, Kim YS, Sung SY, Kwak YK, Kang YN, Jang JS, Kang JH, Hong SH, Kim SJ, Jung SL (2020) Upfront radiosurgery plus targeted agents followed by active brain control using radiosurgery delays neurological death in non-small cell lung cancer with brain metastasis. Clin Exp Metastasis 37:353\u2013363. https:\/\/doi.org\/10.1007\/s10585-020-10022-6","journal-title":"Clin Exp Metastasis"},{"key":"5149_CR28","doi-asserted-by":"publisher","first-page":"28623","DOI":"10.1038\/srep28623","volume":"6","author":"JY Lee","year":"2016","unstructured":"Lee JY, Park K, Lee E, Ahn T, Jung HH, Lim SH, Hong M, Do IG, Cho EY, Kim DH, Kim JY, Ahn JS, Im YH, Park YH (2016) Gene expression profiling of breast Cancer brain metastasis. Sci Rep 6:28623. https:\/\/doi.org\/10.1038\/srep28623","journal-title":"Sci Rep"},{"key":"5149_CR29","doi-asserted-by":"publisher","unstructured":"Tyran M, Carbuccia N, Garnier S, Guille A, Adelaide J, Finetti P, Toulzian J, Viens P, Tallet A, Goncalves A, Metellus P, Birnbaum D, Chaffanet M, Bertucci F (2019) A comparison of DNA mutation and copy number profiles of primary breast cancers and paired brain metastases for identifying clinically relevant genetic alterations in brain metastases. Cancers (Basel) 11. https:\/\/doi.org\/10.3390\/cancers11050665","DOI":"10.3390\/cancers11050665"},{"key":"5149_CR30","doi-asserted-by":"publisher","unstructured":"Angeli E, Bousquet G (2021) Brain metastasis treatment: the place of tyrosine kinase inhibitors and how to facilitate their diffusion across the Blood-Brain barrier. Pharmaceutics 13. https:\/\/doi.org\/10.3390\/pharmaceutics13091446","DOI":"10.3390\/pharmaceutics13091446"},{"key":"5149_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5681\/bi.2012.002","volume":"2","author":"Y Omidi","year":"2012","unstructured":"Omidi Y, Barar J (2012) Impacts of blood-brain barrier in drug delivery and targeting of brain tumors. Bioimpacts 2:5\u201322. https:\/\/doi.org\/10.5681\/bi.2012.002","journal-title":"Bioimpacts"},{"key":"5149_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4161\/mabs.3.2.14239","volume":"3","author":"LA Lampson","year":"2011","unstructured":"Lampson LA (2011) Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. MAbs 3:153\u2013160. https:\/\/doi.org\/10.4161\/mabs.3.2.14239","journal-title":"MAbs"},{"key":"5149_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11523-015-0414-5","volume":"11","author":"JP Bohn","year":"2016","unstructured":"Bohn JP, Pall G, Stockhammer G, Steurer M (2016) Targeted therapies for the treatment of brain metastases in solid tumors. Target Oncol 11:263\u2013275. https:\/\/doi.org\/10.1007\/s11523-015-0414-5","journal-title":"Target Oncol"},{"key":"5149_CR34","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.lungcan.2013.08.013","volume":"82","author":"Y Chen","year":"2013","unstructured":"Chen Y, Wang M, Zhong W, Zhao J (2013) Pharmacokinetic and pharmacodynamic study of gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis. Lung Cancer 82:313\u2013318. https:\/\/doi.org\/10.1016\/j.lungcan.2013.08.013","journal-title":"Lung Cancer"},{"key":"5149_CR35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","volume":"70","author":"Y Togashi","year":"2012","unstructured":"Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70:399\u2013405. https:\/\/doi.org\/10.1007\/s00280-012-1929-4","journal-title":"Cancer Chemother Pharmacol"},{"key":"5149_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, Investigators F (2018) Osimertinib in untreated EGFR-Mutated advanced Non-Small-Cell lung Cancer. N Engl J Med 378:113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137","journal-title":"N Engl J Med"},{"key":"5149_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC, Investigators F (2020) Overall survival with osimertinib in untreated, EGFR-Mutated advanced NSCLC. N Engl J Med 382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662","journal-title":"N Engl J Med"},{"key":"5149_CR38","doi-asserted-by":"publisher","first-page":"20323","DOI":"10.1038\/s41598-023-45815-8","volume":"13","author":"JS Ju","year":"2023","unstructured":"Ju JS, Huang AC, Tung PH, Huang CH, Chiu TH, Wang CC, Ko HW, Chung FT, Hsu PC, Fang YF, Guo YK, Kuo CS, Yang CT (2023) Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC. Sci Rep 13:20323. https:\/\/doi.org\/10.1038\/s41598-023-45815-8","journal-title":"Sci Rep"},{"key":"5149_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/jnci\/dji055","volume":"97","author":"H Shigematsu","year":"2005","unstructured":"Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339\u2013346. https:\/\/doi.org\/10.1093\/jnci\/dji055","journal-title":"J Natl Cancer Inst"},{"key":"5149_CR40","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/1078-0432.CCR-05-1846","volume":"12","author":"GJ Riely","year":"2006","unstructured":"Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839\u2013844. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1846","journal-title":"Clin Cancer Res"},{"key":"5149_CR41","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1158\/1078-0432.CCR-06-0462","volume":"12","author":"DM Jackman","year":"2006","unstructured":"Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Janne PA (2006) Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12:3908\u20133914. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0462","journal-title":"Clin Cancer Res"},{"key":"5149_CR42","doi-asserted-by":"publisher","first-page":"100592","DOI":"10.1016\/j.lanepe.2023.100592","volume":"27","author":"RGP Gijtenbeek","year":"2023","unstructured":"Gijtenbeek RGP, Damhuis RAM, van der Wekken AJ, Hendriks LEL, Groen HJM, van Geffen WH (2023) Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in the netherlands: a retrospective, nationwide registry study. Lancet Reg Health Eur 27:100592. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100592","journal-title":"Lancet Reg Health Eur"},{"key":"5149_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","volume":"17","author":"CS Tan","year":"2018","unstructured":"Tan CS, Kumarakulasinghe NB, Huang YQ, Ang YLE, Choo JR, Goh BC, Soo RA (2018) Third generation EGFR tkis: current data and future directions. Mol Cancer 17:29. https:\/\/doi.org\/10.1186\/s12943-018-0778-0","journal-title":"Mol Cancer"},{"key":"5149_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3978\/j.issn.2218-6751.2014.11.06","volume":"4","author":"EL Stewart","year":"2015","unstructured":"Stewart EL, Tan SZ, Liu G, Tsao MS (2015) Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res 4:67\u201381. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2014.11.06","journal-title":"Transl Lung Cancer Res"},{"key":"5149_CR45","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(15)00246-6","volume":"16","author":"CS Tan","year":"2015","unstructured":"Tan CS, Gilligan D, Pacey S (2015) Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol 16:e447\u2013e459. https:\/\/doi.org\/10.1016\/S1470-2045(15)00246-6","journal-title":"Lancet Oncol"},{"key":"5149_CR46","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jtho.2017.05.018","volume":"12","author":"EE Ke","year":"2017","unstructured":"Ke EE, Zhou Q, Zhang QY, Su J, Chen ZH, Zhang XC, Xu CR, Yang JJ, Tu HY, Yan HH, Zhang YC, Niu FY, Wu YL (2017) A higher proportion of the EGFR T790M mutation May contribute to the better survival of patients with exon 19 deletions compared with those with L858R. J Thorac Oncol 12:1368\u20131375. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.018","journal-title":"J Thorac Oncol"},{"key":"5149_CR47","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12885-018-4075-5","volume":"18","author":"ZF Wang","year":"2018","unstructured":"Wang ZF, Ren SX, Li W, Gao GH (2018) Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis. BMC Cancer 18:148. https:\/\/doi.org\/10.1186\/s12885-018-4075-5","journal-title":"BMC Cancer"},{"key":"5149_CR48","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-10-2692","volume":"17","author":"GR Oxnard","year":"2011","unstructured":"Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA (2011) Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17:1616\u20131622. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2692","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05149-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05149-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:06:34Z","timestamp":1760036794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05149-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["5149"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05149-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6272825\/v1","asserted-by":"object"}]},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors confirm that all authors have contributed to this manuscript, which is a unique submission and is not being considered for publication in part or in full, with any other source in any medium. We also declare that the materials included in this manuscript are not simultaneously under consideration by any other journal. We also certify that there is no ghost writing by anyone not named on the author list, and that all authors have approved the final article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}